Back to top

pharmaceuticals: Archive

Mark Vickery

Top Stock Reports for Merck, Caterpillar & Union Pacific

Merck, Caterpillar and Union Pacific benefit from strong demand, strategic growth drivers and solid cash generation, but face key competitive and execution risks.

CATNegative Net Change MRKNegative Net Change UNPPositive Net Change DJCONegative Net Change CMTVPositive Net Change EMENo Net Change IDXXPositive Net Change GEHCPositive Net Change

Ekta Bagri

Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?

MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.

BMYNegative Net Change MRKNegative Net Change

Zacks Equity Research

Regeneron Wins EC Clearance for Libtayo Dosing Flexibility

REGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.

REGNNegative Net Change SNYNegative Net Change CTMXNegative Net Change

Zacks Equity Research

NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica

Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.

NVSNegative Net Change VCELPositive Net Change ETONNegative Net Change

Kanishka Das

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.

MRKNegative Net Change RHHBYNegative Net Change BMYNegative Net Change MRNANegative Net Change

Zacks Equity Research

Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer

RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.

RVMDNegative Net Change BMYNegative Net Change SMMTNegative Net Change TNGXNegative Net Change

Sundeep Ganoria

How Did AbbVie's Neuroscience Franchise Perform in Q3?

ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion.

ABBVNegative Net Change BIIBPositive Net Change JNJNegative Net Change

Kinjel Shah

AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?

AZN's 16 blockbuster drugs, strong oncology sales and pipeline opportunities support its $80B revenue target, despite generic pressure and clinical setbacks.

AZNNegative Net Change JNJNegative Net Change MRKNegative Net Change LLYNegative Net Change

Kinjel Shah

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

J&J's $2.2 billion Ollin Biosciences deal adds a promising retinal disease candidate, building on acquisitions.

JNJNegative Net Change LLYNegative Net Change GILDNegative Net Change ABBVNegative Net Change

Zacks Equity Research

J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition

JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.

JNJNegative Net Change COLLPositive Net Change VCELPositive Net Change